Sharp J T, Lidsky M D, Duffy J, Thompson H K, Person B D, Masri A F, Andrianakos A A
Arthritis Rheum. 1977 Jul-Aug;20(6):1179-87. doi: 10.1002/art.1780200604.
Two doses of gold sodium thiomalate were compared for their effect on rheumatoid arthritis. Thirty-seven patients with active disease for longer than 6 months were treated with 25 mg of gold sodium thiomalate for an average of 29.6 weeks, then at biweekly or monthly intervals to complete 2 years of treatment. Thirty-eight patients were given more than twice as much gold salt at the same intervals on a flexible dose schedule that produced serum gold levels which averaged 332 microgram/dl during the weekly injection phase. No differences were observed in the therapeutic responses of the two groups. Therefore the minimal dose of gold sodium thiomalate required to induce a response in rheumatoid arthritis is 25 mg or less per week. Serum gold levels in the steady state varied between 95 and 386 microgram/dl and were not related to response. Serum half-life for gold was calculated for patients who had an excellent response and for those who were treatment failures. The rate at which gold disappeared from serum was not related to therapeutic responses.
比较了两剂硫代苹果酸钠金对类风湿性关节炎的疗效。37例活动性疾病超过6个月的患者接受25mg硫代苹果酸钠金治疗，平均治疗29.6周，然后每两周或每月给药一次，完成2年治疗。38例患者按照灵活的给药方案，以相同的间隔给予两倍多剂量的金盐，在每周注射阶段血清金水平平均为332微克/分升。两组的治疗反应没有差异。因此，类风湿性关节炎产生反应所需的硫代苹果酸钠金的最小剂量为每周25mg或更少。稳态血清金水平在95至386微克/分升之间变化，与反应无关。计算了反应良好的患者和治疗失败患者的金血清半衰期。金从血清中消失的速率与治疗反应无关。
